isolated from blood using Ficoll density centrifugation and lysis of erythrocytes. Cells were incubated for 4 hours with 4 mg/ml glycan at 4°C. Used biotinylated glycans include: sialic acid, Lewis-x, mannose, lactosamine, galactosamine and as a negative control glucitol. Glycan binding and identification of immune cell subsets was assessed with flow cytometry using a whole blood flow antibody panel. Results A whole blood flow assay of four healthy donors showed consistent high binding of mannose to B-cells. Interestingly, no binding of mannose was observed to other immune cells indicating that mannose binds specifically to B cells. At this concentration there was no binding of other glycans to leukocytes. When there is a difference in glycan binding between healthy and RA patients CyTOF3-Helios mass cytometer will be used to have a more in-depth analyse of the interacting leukocyte cell subsets. Conclusion This study examines the glycan-binding capacity of leukocytes in healthy donors and RA patients via the whole blood flow assay. Our preliminary data indicates specific binding of mannose to B cells. This is an important finding because B cells play a key role in the pathogenesis of RA, as they produce ACPA and are very efficient in antigen presentation. Further studies on glycan binding to other key immune cells in RA may aid in elucidating their role in the pathogenesis of RA. Gyorgy Nagy.
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CIRCULATING EXOSOMES PLAY A ROLE IN THE REGULATION OF HUMAN IN VITRO OSTEOCLASTOGENESIS
1
Objectives Exosomes (EXOs) belong to the subcellular sized signalosomes called extracellular vesicles (EVs). EVs, which are present in blood and other bodily fluids, carry a broad spectrum of biomolecules that can influence cellular function. It is conceivable that the vesicle composition of EVs is altered in inflammatory diseases, and that this could contribute to disease pathogenesis. Bone tissue is the second biggest consumer of circulating EVs, but the effect of blood derived EXOs on bone homeostasis has not been described before. Our aim was to study the possible role of circulating EVs on the human in vitro osteoclastogenesis in healthy individuals and in those with active arthritis. Methods Blood samples of healthy volunteers, rheumatoid arthritis (RA, DAS: 4.79±1.96) according to the 2010 ACR/ EULAR classification criteria and psoriatic arthritis (PsA, DAS: 2.79±0.72) patients with peripheral arthritis according to the classification criteria for psoriatic arthritis were collected. EXOs were isolated by gravity filtration and ultracentrifugation. To investigate the properties of EXO samples resistive pulse sensing technique, transmission electron microscopy, and western blot were performed. CD14+ cells were separated from PBMCs with positive selection (StemCell), and the cells were stimulated with 50 ng/ml recombinant human M-CSF, RANKL (PeproTech) and blood-derived EXOs. After 7 days, the cells were fixed and stained for tartrate resistant acid phosphatase (TRAP) (Sigma) and the TRAP positive multinucleated cells were counted. Student's t test and one-way ANOVA with Tukey post hoc test were used as statistical analysis. Results EXO characterisation revealed the expression of classical exosome markers (i.e., CD9, CD63, flotilin-1, TSG-101) and an average diameter of 100 nm. Healthy (n=11) and RA derived (n=12) EXOs profoundly inhibited osteoclast differentiation (p<0.01), by contrast the PsA derived (n=10) EXOs had a stimulatory effect (p<0.05). In cross-treatment experiments where EXOs and CD14+ cells were interchanged between the 3 groups, healthy (n=5) and RA (n=5) derived EXOs inhibited (p<0.01) the generation of osteoclasts in all groups, while the PsA (n=7) derived EXOs did not have an inhibitory effect. Conclusions Our abovementioned data suggest that, in a disease-specific manner, circulating EXOs are novel regulators of the human osteoclastogenesis.
BLOOD CHEMOKINE PROFILE IN UNTREATED EARLY RHEUMATOID ARTHRITIS: CXCL10 AS A DISEASE ACTIVITY MARKER
Background/purpose Pathogenic mechanisms in early and preclinical stages of rheumatoid arthritis are unclear. We have recently analysed the profile of T cell subtypes based on chemokine receptor expression in blood from untreated early rheumatoid arthritis (ueRA) patients compared to healthy controls (HC). Here, we compared the levels of the respective chemokines in blood plasma of ueRA patients with those of HC. We also studied the association of chemokine levels with the proportions of circulating T cell subsets and the clinical disease activity. Methods Peripheral blood was obtained from 43 patients with ueRA satisfying the ACR 2010 criteria and who had not received any DMARD or prednisolone, and from 14 sex-and age-matched HC. Proportions of T helper cells in blood, including Th0, Th1, Th2, Th17, Th1Th17, TFh, and regulatory T cells were defined by flow cytometry. Fifteen chemokines, including several CXCL and CCL chemokines related to the T cell subtypes as well as to other major immune cells were measured in blood plasma using flow cytometry beadbased immunoassay or ELISA. Clinical disease activity in patients was evaluated by assessing the following parameters: DAS28, Clinical Disease Activity Index (CDAI), Swollen Joint Counts (SJC), Tender Joint Counts (TJC), CRP and ESR. The data was analysed using multivariate factor analyses followed by univariate analyses. Results Multivariate discriminant analysis showed that patients with ueRA separate from HC based on the blood plasma chemokine profile. The best discriminators were CXCL9, CXCL10, CXCL13, CCL4 and CCL22, which were significantly higher in ueRA compared to HC in univariate analyses. Among the chemokines analysed, only CXCL10 correlated with multiple disease activity measures, including DAS28-CRP, DAS28-ESR, CDAI, SJC in 66 joints, CRP and ESR. Conclusions High circulating levels of CXCL10 in plasma of ueRA and the association with the clinical disease activity suggests that CXCL10 may serve as a disease activity marker in early RA. Background Podocytes are postmitotic visceral epithelial cells, located at the Bowmans capsule of the kidney building up the slit diaphragm with their foot processes to filtrate the blood and keep valuable large proteins in the vessels.
PODOCYTES INTERNALISE DNA-ANTIBODY COMPLEXES
In Systemic Lupus Erythematosus (SLE) different organs are affected by autoantibodies which results in chronic inflammation and a high percentage of patients develop Lupus nephritis (LN) resulting in podocyte damage and disruption of the slit diaphragm. The risk for LN correlates directly with the level of anti-double stranded DNA antibodies (adsDNAabs).
In this study, we wanted to identify the direct effect of adsDNAabs on podocytes. Methods We established an in vitro system to investigate the specific impact of monoclonal antibodies and their immune complexes directly on podocytes (AB8 cell line). Monoclonal antibodies were generated by transfecting HEK293T cell line with Ig heavy and corresponding light chain encoding plasmid DNA obtained from single B cells of patients with SLE and LN. Podocytes were incubated with the produced monoclonal antibodies and the internalisation process and functional consequences were analysed by immunofluorescence, Western Blot, FACS and electron microscopy. For comparison, primary human podocytes were isolated from LN patient urine and analysed by immunofluorescence. Results The recombinantly produced adsDNAabs from LN patients were specific against nuclear structures and build complexes with double stranded DNA, essential for the internalisation by cultivated podocytes. Interestingly, viability and migratory capacity were not influenced by the exposure to adsDNAabs for 48 hour. The internalised antibodies were enclosed by membranous structures and reach the cytosol via clathrin dependent endocytosis. The process of internalisation was time and dose dependent and reversible. Furthermore, internalised antibody complexes could also be detected in primary human LN podocytes. Conclusion In our in vitro model the specific uptake of adsDNAabs was observed, in line with human LN data. Podocytes from patients with LN show IgG positive aggregates in the cytosol. The internalisation depends on the complex formation of the antibodies with dsDNA and could be important part of the LN pathogenesis. -2016-211055.9 Background The urokinase plasminogen activator receptor (uPAR) is expressed mainly on immune cells, smooth muscle cells and endothelial cells, favouring extracellular matrix degradation, cell adhesion, cell proliferation and regulates cell migration. The suPAR is the soluble form of the cell membrane-bound protein uPAR, elevated levels may reflect increased activation of immune system which observed in the autoimmun diseases. The aim of this study was to assess the effects of anti-TNF therapy on these levels in RA and AS patients. The suPAR levels also correlated with various autoimmun inflammatory markers. Patients and methods Altogether 33 arthritis patients including 22 RA patients treated with either etanercept (ETN) or certolizumab pegol (CZP) and 11 AS patients treated with ETN were included in a 12-month follow-up study. Circulating suPAR levels were assessed by suPARnostic Quick Test Reader. In addition,disease activity (DAS28 or BASDAI), CRP, IgM rheumatoid factor, anti-CCP were also assessed. Assessment were performed at baseline, as well as 6 and 12 months after treatment initation. Results Anti-TNF treatment was highly effective in both disease, as the mean DAS28 decreased in RA, mean BASDAI decresead in AS. There were no significant change in the suPAR levels after 12 months of anti-TNF therapy, although resulted non-significant decrease (p<0,18) in RA patients with critical suPAR levels (>9 ng/ml). Baseline suPAR levels positively correlated with anti-CCP (p<0,001) and rheumatoid factor (p=0,024) in RA patients. Circulating suPAR levels did not correlate with DAS28, BASDAI or CRP. Conclusion In a mixed cohort of RA and AS patients, anti-TNF therapy did not affect the suPAR levels after 12 months. No correlations were observed between suPAR levels and CRP, DAS28, BASDAI. suPAR levels correlated with rheumatoid factor and anti-CCP. Based on these results suPAR may be a marker of autoimmunity rather than that of disease activity.
EFFECTS OF ANTI-TNF THERAPY ON SOLUBILE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR (SUPAR) LEVELS IN ARTHRITIS
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SERUM LIPID AND FATTY ACID PROFILES ARE ALTERED IN PATIENTS WITH POLYMYOSITIS OR DERMATOMYOSITIS
